论文部分内容阅读
耐多药肺结核(MDR-TB)是指体外分离的结核菌至少同时耐受传统一线抗痨药物异烟肼和利福平的结核病。伴随全球结核病耐多药上升,我国耐多药结核病流行亦日益严峻,目前已成为全球27个耐多药结核高负担国家之一,每年新增患者12万例[1]。据报道,9.4%MDR-TB为广泛耐多药[2]。因此,积极寻求新的高效抗结核药物成为广大医务科研工作者日益关注的课题。本研究应用左氧氟沙星辅助治疗127例耐多
Multidrug-resistant tuberculosis (MDR-TB) refers to tuberculosis isolated in vitro that is resistant to at least the same first-line TB drugs, isoniazid and rifampicin. With the rise of global MDR-TB, the prevalence of MDR-TB in China is also becoming more and more serious. At present, it has become one of 27 high-burden MDR-TB countries in the world, with 120,000 new cases each year [1]. It has been reported that 9.4% of MDR-TB is multidrug-resistant [2]. Therefore, the active search for new and effective anti-TB drugs has become a topic of increasing concern to medical researchers. In this study, levofloxacin adjuvant treatment of 127 cases of resistance